MYSTERIOUS: 4 - You Need To See This

Eli Lilly Changed Depression Care With Prozac. Now It's Betting on Psychedelics with AtaiBeckley Acquisition

Eli Lilly is making its biggest move yet into the rapidly evolving field of psychedelic medicine, acquiring clinical-stage biotechnology company AtaiBeckley in a deal valued at up to $3.8 billion.

International Business Times · Jul 16

Eli Lilly Is Buying AtaiBeckley in $2.8 Billion Deal. What It Means for LLY Stock

Eli Lilly stock rallies on a $2.8 billion acquisition of AtaiBeckley. Here’s why the deal is bullish for LLY shares.

Barchart · Jul 16

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal

Eli Lilly will acquire AtaiBeckley for up to $3.8 billion. This deal aims to develop psychedelic treatments for depression and other mental health issues. The acquisition includes AtaiBeckley's lead candidate, BPL-003, a nasal spray. This move follows increased interest in psychedelic therapies and federal funding for research. The companies expect…

The Economic Times · Jul 16

Eli Lilly just placed a $40 million bet on the next injectable boom

The GLP-1 maker’s latest AI investment targets drug discovery and the future of consumer medicine.

Fortune · Jul 1

Medicare will soon cover costs of weight-loss drugs. Here’s what you can expect to pay.

Popular Novo Nordisk and Eli Lilly drugs are included

The Independent UK · Jun 29

Six Underrated Stocks Britain's Top Fund Managers Believe Could Deliver Long-Term Growth

Six top fund managers reveal their favourite under-the-radar investments in healthcare, finance, retail, energy, and consumer goods with long-term growth potential despite risks.

International Business Times UK · Jun 29

'He's Such a Fraud': Trump Cakes Bruised Hands in Makeup as Solon Demands Answers Over 'Terminal Illness' Rumours

Donald Trump's bruised hands, visible in new Oval Office photos, have fuelled uneasy questions about his health after he abruptly cancelled a bipartisan housing bill signing.

International Business Times UK · Jun 27

Did Trump Get Experimental Obesity Drug? Rep Lieu Demands Answers Over FDA's 'Powerful Drug' Given to 'Unidentified 79-Year-Old Man'

Representative Ted Lieu questions the White House about claims that President Trump accessed an experimental obesity drug reserved for the gravely ill, sparking controversy and speculation.

International Business Times UK · Jun 25

What Is Retatrutide? The Experimental Weight Loss Drug Millions Cannot Access, But Has Sparked a White House Meltdown Over Trump's Health

A 79-year-old man's access to the experimental drug Retatrutide through the FDA's Expanded Access programme has sparked controversy, with allegations of political insider influence and White House denials.

International Business Times UK · Jun 24

Trump Linked to Mystery FDA Deal Granting Early Access to Powerful Weight-Loss Drug for Critical Patients

A 79-year-old patient received early access to Eli Lilly's experimental obesity drug retatrutide, sparking political and medical controversy amid speculation about the patient's identity.

International Business Times UK · Jun 24